menu
    • menu
    [{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"BSB-1001","moa":"HA-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BlueSphere Bio \/ Celularity","highestDevelopmentStatusID":"7","companyTruncated":"BlueSphere Bio \/ Celularity"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"2","companyTruncated":"BlueSphere Bio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"NMDP BioTherapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"BSB-1001","moa":"HA-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ NMDP BioTherapies","highestDevelopmentStatusID":"5","companyTruncated":"BlueSphere Bio \/ NMDP BioTherapies"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BSB-1001","moa":"HA-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BSB-1001","moa":"HA-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TCX-101","moa":"HA-1 T cell receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TCX-101","moa":"HA-1 T cell receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TCX \u2013 101","moa":"miHA-1","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TCX \u2013 101","moa":"miHA-1","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TCX-101","moa":"HA-1 T cell receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere Bio \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by BlueSphere Bio

    Menu

    BlueSphere Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BSB-1001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Celularity

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Celularity Enters Strategic Collaboration Agreement with BlueSphere Bio

                            Details : The Collaboration will initially focus on the production of BSB’s novel T cell receptor (TCR) T cell therapies including BSB-1001 and TCX-102, using the technical and manufacturing capabilities.

                            Product Name : BSB-1001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 24, 2025

                            Lead Product(s) : BSB-1001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Celularity

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BSB-1001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : NMDP BioTherapies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            BlueSphere Bio Partners with NMDP BioTherapies for TCR-based Product Candidate Trial

                            Details : Through this partnership, BlueSphere will focus on the clinical development of lead product, BSB-1001 for treating patients with relapsed or refractory acute myeloid leukemia.

                            Product Name : BSB-1001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 25, 2024

                            Lead Product(s) : BSB-1001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : NMDP BioTherapies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BlueSphere Collaborates with NCI to Advance Rare Respiratory Disease Treatments

                            Details : The collaboration will seek to advance a novel TCR T-cell therapy, TCX-201, targeting recurrent respiratory papillomatosis (RRP), a rare orphan disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 06, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BSB-1001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BlueSphere Bio Gets IND Clearance for First in Human Candidate in Leukemia

                            Details : BSB-1001 is an investigational T cell receptor (TCR) T-cell therapy developed by BlueSphere Bio. It is baing evaluated for the treatment of acute myeloid leukemia (AML).

                            Product Name : BSB-1001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 06, 2024

                            Lead Product(s) : BSB-1001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BSB-1001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BlueSphere Bio to Present at the Next Generation CAR & T Cell Therapies Conference

                            Details : BSB-1001, targeting the minor HA-1 and part of BlueSphere’s TCX-101 Program, is the first TCR-based clinical candidate generated using TCXpress and is in development for the treatment of AML, ALL and MDS in conjunction with allogeneic hematopoietic ste...

                            Product Name : BSB-1001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 03, 2023

                            Lead Product(s) : BSB-1001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCX – 101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at ...

                            Details : TCX-101 program targets minor histocompatibility antigens by engineering TCR T cells specific to a particular miHA. This allows for achieving graft-vs.-leukemia (GVL) with a lower risk for graft-vs.-host disease (GVHD) in allogeneic hematopoietic stem ce...

                            Product Name : TCX – 101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 26, 2022

                            Lead Product(s) : TCX – 101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCX – 101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BlueSphere Bio to Present at the 7th Annual CAR-TCR Summit

                            Details : TCX-101 program targets minor histocompatibility antigens by engineering TCR T cells specific to a particular miHA. This allows for achieving graft-vs.-leukemia (GVL) with a lower risk for graft-vs.-host disease (GVHD) in allogeneic hematopoietic stem ce...

                            Product Name : TCX – 101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 19, 2022

                            Lead Product(s) : TCX – 101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCX-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BlueSphere Bio Presents New Data Supporting the Potential of its TCXpress Platform at the 2022 AACR Meeting

                            Details : Preclinical data demonstrating the potential of its novel high throughput TCXpress™ platform to efficiently identify TCRs against minor histocompatibility antigens (miHAs) for the future clinical development of adoptive TCR T cell therapy.

                            Product Name : TCX-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 04, 2022

                            Lead Product(s) : TCX-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCX-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BlueSphere Bio Data to be Presented at the 2022 Joint ASTCT + EBMT Basic and Translational Scientific Retreat

                            Details : TCX-101, is a proprietary high-throughput and efficient T-cell receptor (TCR) capture, expression and functional screening platform capable of processing thousands of single T cells directly into functionally expressed TCRs.

                            Product Name : TCX-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 25, 2022

                            Lead Product(s) : TCX-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            BlueSphere Bio

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCX-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BlueSphere Bio Data to be Presented at the 2022 American Association for Cancer Research Annual Meeting

                            Details : TCX-101 program targets minor histocompatibility antigens (miHAs) by engineering TCR T cells specific to a particular miHA. This allows for achieving graft-vs.-leukemia (GVL) with a lower risk for graft-vs.-host disease (GVHD) in allogeneic hematopoietic...

                            Product Name : TCX-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 15, 2022

                            Lead Product(s) : TCX-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth